Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
clinical trials
deals
investing
3
×
life sciences
national blog main
national top stories
roche
3
×
san francisco blog main
san francisco top stories
cancer
fda
sanofi
american society of clinical oncology (asco)
amgen
anti-inflammatory drugs
arcturus therapeutics
avapritinib
avrobio
blueprint medicines
boston
boulder/denver blog main
boulder/denver top stories
brexanolone
camp4 therapeutics
cancer drugs
cancer immunotherapy
cobimetinib
crispr therapeutics
crispr-cas9
cstone pharmaceuticals
denali therapeutics
detroit blog main
detroit top stories
eidos therapeutics
eli lilly
estradiol
european medicines agency
What
cancer
3
×
drug
medicines
ahead
ambien
american
annual
approval
asco
attendees
attention
biotech
blueprint
camp’s
candidate
cash
chicago
city
clinical
combinations
community’s
currently
days
despite
expanding
family
fda
focus
hardest
hit
home
hottest
hunters
ipo
key
kicks
marketing
meeting
muscle
oncology
Language
unset
Current search:
roche
×
cancer
×
investing
×
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More
